In another ASCO 2013 video roundtable, Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).

You can view the video here: http://cancergrace.org/lung/2013/06/10/madeit-sclg-molecular-selection-…

We welcome your questions and comments here.

JimC
Forum moderator

In a new video, Dr. Mary Pinder reviews promising studies from ASCO 2013 on second generation ALK inhibitors LDK-378, CH5424802, and AP26113 in patients with ALK-positive advanced NSCLC, including impressive activity in crizotinib-refractory patients and those with brain mets.

You can view the video here: http://cancergrace.org/lung/2013/06/24/second-generation-alk-inhibitors/

We welcome your questions and comments here.

JimC
Forum moderator

In today's ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

You can view the video here: http://cancergrace.org/lung/2013/07/03/mek-inhibitor-update-asco-2013/

We welcome your questions and comments here.

JimC
Forum moderator

ASCO 2013 videos continue, as Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.

You can view the video here: http://cancergrace.org/lung/2013/07/08/acquired-resistance-targeted-rx-…

We welcome your questions and comments here.

JimC
Forum moderator

In the latest ASCO 2013 video, Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.

You can view the video here: http://cancergrace.org/lung/2013/07/10/integrating-immunotherapies-into…

We welcome your questions and comments here.

JimC
Forum moderator

In the latest ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (docetaxel) as second line therapy for advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/06/19/galaxy-1-ganetespib-hsp90/

We welcome your questions and comments here.

JimC
Forum moderator

GRACE videos from ASCO 2013 continue as Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/06/26/nindetanib-bibf1120-lume-lung-1/

We welcome your questions and comments here.

JimC
Forum moderator

In the first video from the ASCO round table with Drs. Pennell, Pinder and West, the doctors discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC). You can find the video here: http://cancergrace.org/lung/2013/06/07/biomarkers-france-molecular-test…

We welcome your questions and comments here.

JimC
Forum moderator

More breaking news from ASCO 2013, as Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

You can view the video here: http://cancergrace.org/lung/2013/07/05/start-trial-asco-2013/

We welcome your questions and comments here.

JimC
Forum moderator

Each year the oncology world gathers in Chicago in the first week of June for the ASCO (American Society of Clinical Oncology) conference, at which much of the year's major research findings are unveiled. For those who may have an interest in reading about some of the presentations that will be made ASCO has released abstracts that provide basic information about each of these studies. You can browse through those abstracts here: http://abstract.asco.org/176/CatView_176_B.html

JimC
Forum moderator